LifeMD (NASDAQ:LFMD) Issues Earnings Results, Misses Estimates By $0.04 EPS

Key Points

• LifeMD reported a quarterly loss of ($0.06) EPS, missing estimates by $0.04, and has updated its guidance for Q3 and FY 2025.
• The company’s shares fell 4.1% after the earnings announcement, trading at $11.84 despite a 12-month range between $3.99 and $15.84.
• Several analysts maintain positive outlooks, with price targets ranging from $14.00 to $18.00, while the average rating is classified as "Moderate Buy".

LifeMD (NASDAQ:LFMD - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.04), Zacks reports. The company had revenue of $62.22 million for the quarter, compared to the consensus estimate of $66.17 million. LifeMD updated its Q3 2025 guidance to EPS and its FY 2025 guidance to EPS.

LifeMD Trading Up 4.0%

NASDAQ:LFMD traded up $0.27 during mid-day trading on Friday, reaching $6.88. 1,978,725 shares of the company's stock traded hands, compared to its average volume of 1,650,356. The company has a 50 day moving average price of $11.97 and a 200-day moving average price of $8.46. The firm has a market capitalization of $312.47 million, a price-to-earnings ratio of -32.74 and a beta of 1.72. The company has a debt-to-equity ratio of 9.21, a current ratio of 0.77 and a quick ratio of 0.77. LifeMD has a 12-month low of $3.99 and a 12-month high of $15.84.

Insiders Place Their Bets

In related news, CFO Marc David Benathen sold 75,000 shares of the firm's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $13.09, for a total value of $981,750.00. Following the completion of the sale, the chief financial officer owned 389,554 shares of the company's stock, valued at $5,099,261.86. This trade represents a 16.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Eric Harold Yecies sold 15,000 shares of LifeMD stock in a transaction on Friday, June 13th. The shares were sold at an average price of $12.25, for a total transaction of $183,750.00. Following the completion of the sale, the insider owned 16,100 shares in the company, valued at approximately $197,225. This trade represents a 48.23% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 275,000 shares of company stock valued at $3,564,550 over the last three months. 18.40% of the stock is currently owned by corporate insiders.

Institutional Trading of LifeMD

A hedge fund recently raised its stake in LifeMD stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of LifeMD, Inc. (NASDAQ:LFMD - Free Report) by 4.7% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 49,647 shares of the company's stock after purchasing an additional 2,235 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 0.11% of LifeMD worth $270,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 35.52% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on LFMD. Lake Street Capital dropped their target price on LifeMD from $18.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday. KeyCorp lowered their price objective on shares of LifeMD from $14.00 to $12.00 and set an "overweight" rating for the company in a report on Wednesday. BTIG Research upped their price objective on shares of LifeMD from $15.00 to $18.00 and gave the company a "buy" rating in a research note on Wednesday, June 18th. Wall Street Zen downgraded shares of LifeMD from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Finally, HC Wainwright reduced their price objective on LifeMD from $14.00 to $13.00 and set a "buy" rating on the stock in a research note on Thursday. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $12.86.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.